Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while YieldMax NVDA Option Income Strategy ETF trades at $12.63. Which is the better fit depends on your goals.
| ALNY | NVDY | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $491.22 | $17.96 |
52-Week Low | $278.09 | $12.03 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.75, up 2.66% today, amid a bearish technical signal. The fund generates weekly dividends from selling options on NVIDIA stock, with recent payouts ranging from $0.10 to $0.21. Key support sits at $12, resistance at $13, while RSI readings are neutral but ADX indicates a strong downtrend. News highlights focus on the trade-off between income and missing NVIDIA's upside potential.
Outlook hinges on NVIDIA's volatility sustaining option premiums, offering high yield but capped gains. Risks include underperformance if NVIDIA rallies sharply and reliance on options strategy execution. The fund appeals to income-focused investors willing to sacrifice growth for distributions, with sentiment mixed due to opportunity cost concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
